Schrodinger Inc(SDGR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:47 PM ET (Korea 10/30 08:47)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.74 | Insider Own | 15.38% | Shs Outstand | 65.6M | Perf Week | 32.7% |
| Market Cap | 2.24B | Forward P/E | - | EPS next Y | 12% | Insider Trans | -0.28% | Shs Float | 63.3M | Perf Month | -3.41% |
| Enterprise Value | 1.93B | PEG | - | EPS next Q | -0.67 | Inst Own | 84.78% | Short Float | 16.43% | Perf Quarter | 98.08% |
| Income | -0.05B | P/S | 8.66 | EPS this Y | -16.6% | Inst Trans | 0.1% | Short Ratio | 5.31 | Perf Half Y | 150.75% |
| Sales | 0.26B | P/B | 6.82 | EPS next 5Y | 13.73% | ROA | -8.18% | Short Interest | 10.40M | Perf YTD | 67.73% |
| Book/sh | 4.4 | P/C | 5.36 | EPS past 3/5Y | 12.46% -28.1% | ROE | -16.18% | 52W High | -11.22% ($33.78) | Perf Year | 41.8% |
| Cash/sh | 5.6 | P/FCF | - | Sales past 3/5Y | 12.24% 18.81% | ROIC | -12.92% | 52W Low | 174.01% ($10.94) | Perf 3Y | 38.52% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 70.36% | Gross Margin | 56.87% | Volatility(W/M) | 9.41% 8.25% | Perf 5Y | -45.05% |
| Dividend TTM | - | EV/Sales | 7.46 | Sales Y/Y TTM | 8.88% | Oper. Margin | -59.24% | ATR (14) | 2.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.71 | EPS Q/Q | 113.42% | Profit Margin | -20.98% | RSI (14) | 61.92 | Recom | 1.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.71 | Sales Q/Q | 7.54% | SMA20 | 13.9% ($26.33) | Beta | 1.68 | Target Price | $25.86 |
| Payout | - | Debt/Eq | 0.33 | Earnings | 2026/11/4 | SMA50 | 20.9% ($24.81) | Rel Volume | 0.7 | Prev Close | $30.87 |
| Employees | 850 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | 119.3% 24.8% | SMA200 | 79.45% ($16.71) | Avg Volume(3M) | 1.96M | Price | $29.99 |
| IPO | 2020/2/6 | Option/Short | Yes/Yes | Trades | 13429 | Volume | 1,364,902 | Change | -2.85% |
🧬 Schrödinger (SDGR) is a US computational sciences company that designs novel drug and new-material molecules through its physics-based computing platform. Built on long-accumulated R&D, the company licenses its software to pharmaceutical, biotech, and industrial firms as well as academic institutions, while simultaneously running its own and partnered drug discovery pipelines — a dual business model.
Over the past 1 year, on the higher side
11% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
Next earnings report: November 4
5 days to go.
SDGR has a sound balance sheet but weak earning power
Of every $100 in sales, $59.24 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -16.6% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $866. Peers typically go for $181. It is about in line with its own 1-year average.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -45.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 84.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #10 of 41 in the industry
Based on market cap of $2B.
PRVA#9 Privia Health Group Inc $3B PER 102.1 SDGR#10 Schrodinger Inc $2B PER - 
CERT#11 Certara Inc $2B PER - 
OMCL#12 Omnicell Inc $2B PER 43.6 
TDOC#13 Teladoc Health Inc $2B PER - 
FAQ
What kind of company is SDGR?
SDGR belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of SDGR?
The market cap of SDGR is approximately $2.2B, ranking 1,974 within its sector.
What is the 52-week high and low for SDGR?
SDGR has recorded a 52-week high of $33.78 and a low of $10.94.
